...that??’–it’s time to take a step back from the screen and do something constructive like rebuild an engine or take a swim. Having observed or worked for companies in bubbles since 1980 in three industries– post-deregulation airlines in the 1980s, internet (dot.com) from the mid-1990s to 2001, first stage telecare/telehealth (2006-8), and healthcare today (Theranos/Outcome Health), a moderate bubble never, ever deflates–it expands, then bursts. The textbook #3 was the dot.com boom/bust; it not only fried internet companies but many vendors all over the US and kicked off a recession. Rock Health also downplayed #5, fraud and misuse of funds.... Continue Reading
Search Results for "outcome health"
SNF emergency telehealth provider Call9 shuts down most operations, after $34M raise (updated)
...peak, leaving their founders and some employees cheerful indeed. On the other hand, and far more common: the demise of some is understandable, others regrettable, and nearly none of them are cause for celebration in our field–Theranos and Outcome Health being exceptions. This Editor has been a marketing head of two of them (now deceased except for their technology, out there somewhere), and has discussed marketing, funding, and business models with more startups and early-stage companies than she can count. If anything, investors have less patience than they did back in the Grizzled Pioneer period of the early 2000s, when... Continue Reading
Where’s the evidence? Healthcare unicorns lack the proof and credibility of peer-reviewed studies.
...dearth of peer-reviewed research among healthcare unicorns–and that it’s detrimental. It measured whether these unicorns published peer-reviewed articles and whether they publish highly-cited (in other publications) articles; compared them against companies with lower valuations; and whether founders or board members themselves impacted the scientific literature through their own citations. The meta-study looked at 18 current and 29 exited healthcare unicorns. Highlights: Two companies–23andMe and Adaptive Biotechnologies published almost half of all unicorn papers–196 combined Three unicorns (Outcome Health, GuaHao and Oscar Health) had no published papers, and two more (Clover Health, Zocdoc) had published just one Seven of the exited... Continue Reading
It’s Official: CES is now a health tech event (updated)
...is here. Dr. Jayne at HISTalk also did an excellent health-related product roundup in her Curbside Consult column. Mobihealthnews also has a very long running list of health tech pictures and announcements as part of its limited coverage, including the mea culpas and promised transparency of onetime health ed unicorn Outcome Health [TTA 29 Jan 18]. Beyond the plethora of products encouraging ever more to come forward, what ones will even make it to market, far more be winners? Aside from the Samsungs and P&Gs, which of these young companies planting their stake at CES will be there next year?... Continue Reading
2017’s transition in digital health funding: is it maturity or a reconsideration?
...million in value, which excludes much of the action from young and international companies: No digital health IPOs this year, in a weak year in general for IPOs For the companies already in public markets, they outperformed the S&P 500 31 percent to 19 percent Average deals hit an all-time high of $16.7M ($5.8 bn over 345 deals) Big money went to better-developed, more mature companies like Outcome Health and Peloton exercise equipment at $500 million and $325 million. Rock Health duly notes Outcome Health’s troubles since. (To this Editor, Peloton is not a digital health company despite its glitzy... Continue Reading
Another unicorn loses its horn–Outcome Health finally loses the CEO and president
[grow_thumb image=”https://telecareaware.com/wp-content/uploads/2015/08/1107_unicorn_head_mask_inuse.jpg” thumb_width=”150″ /]Another Theranos? Outcome Health is a point of ‘sale’ advertising company that has wrapped itself in ‘behavior change technology’. It’s been a Chicago darling and closed a $500 million Series A led by Goldman Sachs and Alphabet only last May. Its business in ‘transforming healthcare’ is the prosaic but highly lucrative placement of monitors in doctors’ offices that provide relentless health educational content liberally laced with DTC sponsorship messages, free to the doctors but paid for by pharma companies. This also includes tablets, exam room demo wallboards, and Wi-Fi in offices. The Series A pushed up the... Continue Reading
StartUp Health’s Q3 is an even crazier $9bn YTD
...than ever at an average $18 million versus $14 million in 2016 Half the deals they tracked were in personalized health and patient/consumer experience, a distinct difference from Rock Health’s shift to B2B. Population health held its own. They tracked more mega-deals YTD due to broader category and ex-US. Rock Health’s lead this quarter of 23andMe was only #6 on the list, surpassed by Auris, Peloton, Guardant Health, Outcome Health, and Grail. The Bay Area leads for deals substantially YTD, with NYC, Boston, and Chicago combined still trailing Remember that StartUp Health takes a wider sample than Rock Health [TTA... Continue Reading
‘Record-shattering’ Q2 for digital health deals: Rock Health’s volte-face
...Looking at trends, the average deal size has ballooned to $18.7 million from the 2015-16 range of $14 million. Seven $100 million+ deals led the way: Outcome Health, Peloton, Modernizing Medicine, PatientPoint, Alignment Healthcare, PatientsLikeMe, and ShareCare. Of these, three are consumer health information (Outcome, PatientPoint, ShareCare), with PatientsLikeMe closely related with a patient community focus; as the lead category of investment overall, there’s now gold in consumer health. All seven businesses are located outside of Silicon Valley, a refreshing change. A surprise is Modernizing Medicine in the settled (we thought) EHR-clinical workflow category. There’s also an interesting analysis of... Continue Reading
Most Recent Comments